GTS-21
GTS-21 is a derivative of the natural product anabaseine that acts as a partial agonist at neural nicotinic acetylcholine receptors. It binds to both the α4β2 and α7 subtypes, but activates only the α7 to any significant extent.
Both GTS-21 itself and its demethylated active metabolite 4-OH-GTS-21 display nootropic and neuroprotective effects, and GTS-21 is being investigated for the treatment of Alzheimer's disease, nicotine dependence, and, most significantly, for schizophrenia.
The laboratory name GTS-21 means that it is the 21st chemical compound created by Gainesville and Tokushima Scientists. DMXB-A – 3-2,4-dimethoxybenzylidene anabaseine.
